Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00698152 · ClinicalTrials.gov registry record

A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement

A clinical trial of Rheumatoid Arthritis and Osteoarthritis, sponsored by Zimmer Biomet.

Completed
Registry status
149
Enrollment target
5
Study locations

NCT00698152 is a study of Rheumatoid Arthritis and Osteoarthritis that has completed, run by Zimmer Biomet. The registered enrollment target is 149 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00698152, a study of Rheumatoid Arthritis and Osteoarthritis, has completed, sponsored by Zimmer Biomet.

COMPLETED
Registry status
149 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked polyethylene

Study Locations (5)

Ohio

  • The Orthopaedic Institute of Ohio - Lima
  • Ohio Valley Orthopedic and Sports Medicine - West Chester

Maryland

  • The Orthopaedic Center - Rockville

Pennsylvania

  • Scranton Orthopaedic Specialists, PC - Dickson City

Texas

  • Texas Orthopedic Specialists, PA - Grapevine

Trial Details

FieldValue
Enrollment Target 149 participants
Start Date 2006-01-23
Est. Completion 2016-01-15

Sponsor

Zimmer Biomet

115 total trials

What the Registry Record Tells You About NCT00698152

The ClinicalTrials.gov registry entry for NCT00698152 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT00698152 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Maryland, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00698152 about?

NCT00698152 is a clinical study titled "A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement". The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked polyethylene

What is the current status of trial NCT00698152?

This trial is currently completed. The enrollment target is 149 participants. The study started on 2006-01-23. Estimated completion is 2016-01-15.

What conditions does trial NCT00698152 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Osteoarthritis, Avascular Necrosis.

Who is sponsoring clinical trial NCT00698152?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00698152 being conducted?

This trial has 5 study locations across Maryland, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.